Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

CASI Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market with a commercial focus on China, announces that ZEVALIN is now available at hospitals in Hong Kong to patients with indicated non-Hodgkin's lymphoma (NHL), including at Hong Kong Sanatorium & Hospital.

20 Jul 2015

New treatment improves outcome for early FDG-PET-positive patients with stages I/II Hodgkin lymphoma

Final results of the randomized intergroup EORTC, LYSA (Lymphoma Study Association), FIL (Fondazione Italiana Linfomi) H10 trial presented at the 13th International Conference on Malignant Lymphoma in Lugano, Switzerland, on 19 June 2015 show that early FDG-PET ( 2-deoxy-2[F-18]fluoro-D-glucose positron emission tomography) adapted treatment improves the outcome of early FDG-PET-positive patients with stages I/II Hodgkin lymphoma.

16 Jul 2015

Mayo Clinic awarded $11 million NCI grant to study survivorship in patients with non-Hodgkin lymphoma

Mayo Clinic announced today that it has received a five-year, $11 million grant from the National Cancer Institute to study survivorship in patients with non-Hodgkin lymphoma (NHL). The Lymphoma Epidemiology of Outcomes Cohort Study will enroll 12,000 patients with NHL. The study will follow these patients for long-term prognosis and survivorship.

9 Jul 2015

Two years may be a more practical survival goal for patients with follicular lymphoma

The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular lymphoma.

30 Jun 2015

Current treatments for blood cancer priced too high to be considered cost-effective, new analysis finds

The costs associated with cancer drug prices have risen dramatically over the past 15 years, which is of concern to many top oncologists. In a new analysis, researchers at The University of Texas MD Anderson Cancer Center concluded the majority of existing treatments for hematologic, or blood, cancers are currently priced too high to be considered cost-effective in the United States.

23 Jun 2015

Helmholtz Zentrum München scientists identify how Epstein-Barr virus conceals in human cells

Scientists at Helmholtz Zentrum München have now discovered how Epstein-Barr virus (EBV) conceals itself in human cells. A main culprit for its bad visibility by the immune system is the viral protein LMP2A. As published in the scientific journal PLOS Pathogens, the protein helps EBV-infected cells hide from T cells. This camouflage through the LMP2A protein may play a major role in the causation of cancer by EBV.

16 Jun 2015

Non-invasive prenatal testing can detect maternal cancer at early stage

Non-invasive prenatal testing (NIPT) for chromosomal foetal disorders is used increasingly to test for conditions such as Down's syndrome. NIPT examines DNA from the foetus in the mother's blood, and therefore does not carry the risk of miscarriage involved in invasive testing methods.

7 Jun 2015

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

Janssen Research & Development, LLC has initiated the rolling submission of its Biologic License Application (BLA) for daratumumab to the U.S. Food and Drug Administration (FDA) for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD), or who are double refractory to a PI and an IMiD.

7 Jun 2015

New article published in Spanish Journal of Pathology highlights a rare case of Hodgkin's lymphoma

Dr. Jerónimo Forteza, Professor of Pathology and Director of the Valencian Institute of Pathology, Catholic University of Valencia "San Vicente Mártir," recently published an article in the Spanish Journal of Pathology on the case of a patient with Hodgkin's lymphoma. Medicine student Pablo Sánchez Vela performed this diagnostic work under the supervision of Dr. Forteza.

3 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

MorphoSys AG today announced updated clinical data on its proprietary drug candidate MOR208. MOR208 is a potent anti-CD19 antibody with a proprietary modification to the Fc portion that is being developed to treat B-cell malignancies.

2 Jun 2015

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Data from the international, multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment with single-agent daratumumab – an investigational, human anti-CD38 monoclonal antibody – achieved an overall response rate (ORR) of 29.2 percent (95% CI, 20.8-38.9), as assessed by an independent review committee, in heavily pre-treated patients with multiple myeloma.

30 May 2015

Hodgkin's lymphoma treatment can cause late sequelae

Hodgkin's lymphoma--cancer of the lymph nodes--arises in more than 150 children and adolescents in Germany each year. Nine out of ten patients survive the disease, thanks to the highly effective treatments that are now available. Depending on the type of treatment given, however, there may be late sequelae, as discussed by Wolfgang Dörffel and colleagues in an original article in the current issue of Deutsches Ärzteblatt International (Dtsch Arztebl Int 2015; 112: 320-7).

29 May 2015

Study: New cases of cancer rising globally, but death rates falling in many countries

New cases of virtually all types of cancer are rising in countries globally - regardless of income - but the death rates from cancer are falling in many countries, according to a new analysis of 28 cancer groups in 188 countries.

29 May 2015

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies, announces that it has signed an agreement with Genmab A/S to jointly research, develop and commercialize multiple bispecific antibodies for cancer immunotherapy using proprietary technologies from both companies: BioNTech's proprietary immunomodulatory antibodies and Genmab's DuoBody technology platform.

19 May 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19.

17 May 2015

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

The combination of a cholesterol-lowering drug, Bezafibrate, and a contraceptive steroid, Medroxyprogesterone Acetate, could be an effective, non-toxic treatment for a range of cancers, researchers at the University of Birmingham have found.

15 May 2015

Persistent enlarged lymph glands in the neck may indicate cancer

Referring patients with unexplained swollen neck glands for specialist investigations could help to avoid some of the thousands of deaths each year from lymphoma, a type of cancer.

27 Apr 2015

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Results announced today at The International Liver Congress 2015 show that cancer rates in patients with the hepatitis C virus (HCV) were significantly increased compared to the non-HCV cohort. The researchers suggest an extrahepatic manifestation of HCV may be an increased risk of cancer.

25 Apr 2015

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

In a paper published in the New England Journal of Medicine, the scientists show that a positron-emission tomography (PET) scan immediately after treatment with chemotherapy can identify patients who have a very good outcome without additional radiotherapy.

23 Apr 2015

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

ZEVALIN drug now available to non-Hodgkin's lymphoma patients in Hong Kong

New treatment improves outcome for early FDG-PET-positive patients with stages I/II Hodgkin lymphoma

Mayo Clinic awarded $11 million NCI grant to study survivorship in patients with non-Hodgkin lymphoma

Two years may be a more practical survival goal for patients with follicular lymphoma

Current treatments for blood cancer priced too high to be considered cost-effective, new analysis finds

Helmholtz Zentrum München scientists identify how Epstein-Barr virus conceals in human cells

Non-invasive prenatal testing can detect maternal cancer at early stage

Janssen begins rolling submission of daratumumab BLA to FDA for treatment of patients with multiple myeloma

New article published in Spanish Journal of Pathology highlights a rare case of Hodgkin's lymphoma

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

Daratumumab achieves 29.2% overall response rate in heavily pre-treated patients with multiple myeloma

Hodgkin's lymphoma treatment can cause late sequelae

Study: New cases of cancer rising globally, but death rates falling in many countries

BioNTech, Genmab to jointly develop and commercialize immunomodulatory antibodies for cancer

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

Combination of contraceptive and cholesterol-lowering drugs kills cancer cells in a new way

Persistent enlarged lymph glands in the neck may indicate cancer

Study: Cancer rates in HCV patients significantly increase compared to non-HCV cohort

Study shows that Hodgkin lymphoma patients can remain disease-free with just chemotherapy alone

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Hodgkin's Lymphoma News and Research

Latest Hodgkin's Lymphoma News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in